This is an open label, randomized phase II study designed to evaluate the tolerability and response rate of high-dose and low-dose regimens in patients with advanced cutaneous T-cell lymphoma (CTCL) who have had progressive, recurrent, or persistent disease on or following 2 systemic therapies.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Sapacitabine
Phase: Phase 2
Ages Eligible For Study:
- Adult patients with advanced CTCL - Have had at least 2 systemic therapies - Must have evaluable disease - Eastern Cooperative Oncology Group performance status 0-2 - Adequate bone marrow, hepatic and renal function - At least 3 weeks from prior therapies - Not receiving topical steroids or have been on a stable dose of topical steroids for at least 2 weeks - Able to swallow capsules - At least 3 weeks from major surgery - Agree to practice effective contraception - Able to understand and willing to sign the informed consent form